RGLS Company Profile and Key Details

Regulus Therapeutics Inc. generated EPS of -$0.73 over the past year. Five-year average earnings growth is 40.21%. Wall Street analysts project EPS growth of 11.89% annually over the next five years. The latest quarter delivered EPS of -$0.17. The next quarter is forecast at -$0.21. Next year's EPS is expected at $0.21. Analyst sentiment is bullish. Analyst rating data shows there are 1 Strong Buy ratings, 3 Buy ratings, 1 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $28.00 to $6.00. The high target offers 243.14% upside. The low target suggests -26.47% downside. The mean target is $12.20. This offers 49.51% upside. Regulus Therapeutics Inc. earnings surprise history is a mixed track record. The quarter that ended August 14, 2025, missed forecasts by -26.09%. The prior quarter beat by -48.28%. Over the last six quarters, Apple has recorded several small beats. These include 93.33% in May 09, 2024.

Regulus Therapeutics Inc. has 69.23 million shares outstanding. The public float is 57.67 million shares, elevated short interest at 3.83% of float. This equals 2.09 million shares. The short ratio is 0.81 days. Institutional investors hold 85.18% of the float. Insiders own 2.71%. MOTT DAVID M holds 900.90 thousand shares, BARRIS PETER J has 900.90 thousand shares and DENNER ALEXANDER J has 423.16 thousand shares.

Regulus Therapeutics Inc. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around $0.68. This means the shares are trading above this model’s fair value.

Regulus Therapeutics Inc. trades at a P/E ratio of -14.8, slightly below the S&P 500 average, with a price-to-sales ratio of 1661.62 and a price-to-book ratio of 7.82 trading at moderately above to book value. The P/FCF stands at -17.84, also above market averages.

The stock is currently within 5% of its 52-week high $0.83 and $8.35. With a market capitalization of about $564.95 million, Regulus Therapeutics Inc. is classified as a small-cap and shows lower-than-market volatility (beta ~0.37). Key stats such as the average daily volume over the past year has been around 2.16 million shares, trading with heavier-than-usual volume. Headquartered in San Diego, CA, Regulus Therapeutics Inc. operates in the Healthcare sector and the Biotechnology industry. Led by CEO Joseph P. Hagan, the company employs approximately 34 people and listed since October 09, 2012. Regulus Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the discovery and development of drugs that targets microRNAs to treat a range of diseases in the United States.

Regulus Therapeutics Inc. (NASDAQ:RGLS) shares are up 416.46% year-to-date currently trading near 52-week highs band. Short-term momentum has been positive over the last quarter, despite recent volatility. Valuation shows Regulus Therapeutics Inc. trading at a premium to the broader market with a P/E of -14.8. Analyst sentiment is cautious, with the majority of ratings in Market Perform territory and a mean price target of $11.34, suggesting 38.97% upside. Our AI forecast model points to short-term weakness (-1.23% over two weeks), a medium-term rise (133.21% over three months), and a longer-term gain (350.12% over one year), with expected trading ranges indicating moderate volatility.

Our AI price prediction model suggests that Regulus Therapeutics Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected decline of -1.23%, with price expected at $8.06 by July 09, 2025, within a range of $7.96 to $8.16 3-Month Outlook: Projected rise of 133.21%, reaching $19.03 by September 23, 2025, with a range of $18.91 to $19.15. 1-Year Outlook: Projected gain of 350.12%, with price at $36.73 by June 25, 2026, within a range of $39.96 to $40.97.